Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novo-Nordisk A/S

62.62
+0.54000.87%
Pre-market: 62.810.1900+0.30%04:16 EDT
Volume:6.28M
Turnover:392.60M
Market Cap:277.97B
PE:19.93
High:63.25
Open:62.19
Low:61.97
Close:62.08
Loading ...

Why Novo Nordisk Stock Popped on Friday

Motley Fool
·
21 Feb

FDA declares Wegovy and Ozempic shortage over, Novo Nordisk confirms

TIPRANKS
·
21 Feb

Novo Nordisk's Shortage of Ozempic, Wegovy Resolved

MT Newswires Live
·
21 Feb

Hims & Hers Health Shares Fall Pre-Bell as US FDA Says Ozempic, Wegovy Shortages Have Ended

MT Newswires Live
·
21 Feb

Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats

Reuters
·
21 Feb

Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over

TIPRANKS
·
21 Feb

Novo Nordisk A/S (NVO): Is It The Most Oversold Healthcare Stock to Buy Now?

Insider Monkey
·
21 Feb

Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...

GuruFocus.com
·
21 Feb

Who is Singaporean biotech tycoon Huang Zhenhua, whose assets have been frozen over US$830m suit by Novo Nordisk

CNA
·
21 Feb

European Equities Close Lower in Wednesday Trading; UK Inflation Rises Higher Than Expected

MT Newswires
·
20 Feb

Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud

MT Newswires Live
·
19 Feb

Novo Nordisk (0QIU) Gets a Buy from Goldman Sachs

TIPRANKS
·
19 Feb

Singapore court freezes worldwide assets in US$830 million Novo Nordisk suit

businesstimes
·
19 Feb

Novo Nordisk call volume above normal and directionally bullish

TIPRANKS
·
19 Feb

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading

MT Newswires Live
·
19 Feb

Novo Nordisk A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
18 Feb

UBS Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

TIPRANKS
·
17 Feb

Deutsche Bank Keeps Their Buy Rating on Novo Nordisk (0QIU)

TIPRANKS
·
17 Feb

Novo Nordisk A/S (NVO): Among the Best Drug Stocks to Buy Now

Insider Monkey
·
17 Feb

2 Important Insights From Novo Nordisk's Earnings Call

Motley Fool
·
16 Feb